首页> 外文期刊>Cancer causes and control: CCC >Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States).
【24h】

Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States).

机译:非甾体类抗炎药的使用与晚期和非晚期大肠腺瘤复发的减少相关(美国)。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To prospectively examine the association between non-steroidal anti-inflammatory drugs (NSAIDs) use (including dose and dosage schedule) and the recurrence of colorectal adenomas among individuals who were diagnosed with an adenoma at entry into a clinical trial. METHODS: For this analysis, participants who completed the full follow-up (n = 1905) for the Polyp Prevention Trial (PPT) were evaluated. Information on current use and dose of NSAIDs and other drugs was obtained at baseline and at each subsequent study visit over the duration of the trial. The study endpoint was the recurrence of colorectal adenomas in the 3 years between the 1-year trial colonoscopy (T1) and the end of the trial colonoscopy (T4). RESULTS: There was a significant reduction in overall adenoma recurrence among NSAIDs users (odds ratio [OR] = 0.77; 95% confidence interval [CI]: 0.63-0.95), with the greatest effect seen in advanced polyps (OR = 0.51; CI: 0.33-0.79). Among aspirin users, we observed a significant dose response for overall adenoma recurrence, with a 40% reduction in the OR association (OR = 0.56; 95% CI: 0.31-0.99) among those taking more than 325 mg per day. CONCLUSION: This prospective study provides further evidence that NSAIDs may play an important role in the chemoprevention of recurrent colorectal adenomas, even those with advanced features.
机译:目的:前瞻性研究非甾体抗炎药(NSAIDs)的使用(包括剂量和用药时间表)与在临床试验中被诊断出患有腺瘤的个体中结直肠腺瘤复发之间的关系。方法:为进行此分析,对完成息肉预防试验(PPT)的完整随访(n = 1905)的参与者进行了评估。在试验过程中,在基线以及随后的每次研究访问中均获得了有关NSAIDs和其他药物当前使用和剂量的信息。研究终点是从1年试验结肠镜检查(T1)到试验结肠镜检查结束(T4)之间的3年中大肠腺瘤的复发。结果:NSAIDs使用者的整体腺瘤复发率显着降低(优势比[OR] = 0.77; 95%置信区间[CI]:0.63-0.95),对晚期息肉的影响最大(OR = 0.51; CI) :0.33-0.79)。在阿司匹林使用者中,我们观察到总体腺瘤复发有显着的剂量反应,每天服用325毫克以上的人中OR关联降低40%(OR = 0.56; 95%CI:0.31-0.99)。结论:这项前瞻性研究提供了进一步的证据,表明非甾体抗炎药可能在复发性结直肠腺瘤的化学预防中发挥重要作用,即使那些具有晚期特征的腺瘤也是如此。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号